Literature DB >> 31110116

SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.

Joseph I Wolfsdorf1, Robert E Ratner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31110116     DOI： 10.2337/dci19-0008

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  9 in total

Review 1.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

Review 2.  Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus.

Authors:  Rebecca J Vitale; Lori M Laffel
Journal:  Adv Chronic Kidney Dis       Date:  2021-07       Impact factor: 4.305

3.  A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes.

Authors:  John M Wentworth; Spiros Fourlanos; Peter G Colman; Leonard C Harrison
Journal:  Metabol Open       Date:  2020-01-03

4.  Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide.

Authors:  Sih Min Tan; Runa S J Lindblom; Mark Ziemann; Adrienne Laskowski; Cesare Granata; Matthew Snelson; Vicki Thallas-Bonke; Assam El-Osta; Carlos D Baeza-Garza; Stuart T Caldwell; Richard C Hartley; Thomas Krieg; Mark E Cooper; Michael P Murphy; Melinda T Coughlan
Journal:  Nutrients       Date:  2021-04-25       Impact factor: 6.706

5.  Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.

Authors:  Andrew P McGovern; Michael Hogg; Beverley M Shields; Naveed A Sattar; Rury R Holman; Ewan R Pearson; Andrew T Hattersley; Angus G Jones; John M Dennis
Journal:  BMJ Open Diabetes Res Care       Date:  2020-05

Review 6.  Nutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications.

Authors:  Christine A March; Dorothy J Becker; Ingrid M Libman
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

Review 7.  Current and future therapies for type 1 diabetes.

Authors:  Bernt Johan von Scholten; Frederik F Kreiner; Stephen C L Gough; Matthias von Herrath
Journal:  Diabetologia       Date:  2021-02-17       Impact factor: 10.122

8.  Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.

Authors:  Ghasem Yadegarfar; Mark Livingston; Gabriela Cortes; Ramadan Alshames; Kate Leivesley; Ann Metters; Linda Horne; Tom Steele; Adrian H Heald
Journal:  Cardiovasc Endocrinol Metab       Date:  2021-03-25

Review 9.  Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.

Authors:  Biff F Palmer; Deborah J Clegg
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-09       Impact factor: 10.614
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.